TokenPost topic
Eli Lilly
32 TokenPost stories are tagged Eli Lilly. The newest appear first.
Latest Eli Lilly stories
- Health Canada Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction
The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.
· Regulation
- Rhythm Pharmaceuticals Shares Rise 5.4% by 12:22 p.m. ET
Viking Therapeutics was also part of speculation about two possible obesity-market targets.
· Business
- Stipple Bio Announces Lilly Cancer Deal Valued at Up to $5.9 Billion
Stipple Bio announced the exclusive worldwide agreement on Nov. 16.
· Business
- Eli Lilly to Buy Calytrix Bio in All-Cash Deal Worth Up to $1.5 Billion
Calytrix Bio is a privately held biotechnology company, and the transaction is structured as an all-cash deal.
· Business
- Eli Lilly Study Finds Weight Reductions in Adolescents With Zepbound
Participants had obesity or excess weight and related health conditions.
· Business
- Analysts Highlight Obesity Drugs and Sales Growth in Pharma Picks
Lilly’s tirzepatide and retatrutide featured alongside Gilead’s 6.8% revenue growth and a 35% rise in Sanofi’s Dupixent sales.
· Insights & Views
- Top 30 pharma companies reach $5 trillion in market value, rivaling big software
The top 30 pharmaceutical companies have roughly $5 trillion in market value. Andreessen Horowitz compares their scale and leading drug revenues with major software businesses.
· Insights & Views
- China Approves Eli Lilly’s Orforglipron Weight-Loss Pill
Lilly is the first drugmaker to receive Chinese clearance for a GLP-1 weight-loss pill, giving it an early lead over Novo Nordisk.
· Regulation
- Eli Lilly Sued Over Rep’s Retaliation Claim Tied to Alleged Off-Label Mounjaro Promotion
Jennifer Mansion alleges Eli Lilly and Co. fired her after she objected to its alleged off-label promotion of Mounjaro for weight loss, an unapproved use at the time.
· Regulation
- Eli Lilly’s Foundayo Cuts Sleep Apnea Events in Two Phase 3 Trials
The 712-person studies found fewer breathing interruptions at week 52 with the pill than placebo, with or without positive airway pressure therapy. Lilly plans to submit the results to the FDA by year-end.
· Business
- Binance Sets November Dividend Snapshots for Four bStocks Tokens
Net dividends will be reinvested in additional units of the corresponding securities and distributed in token form.
· Business
- LifeMD Adds Mail-Order Option for Lilly’s Zepbound and Foundayo
Eligible patients need a prescription after an independent clinical evaluation; purchases are cash-pay at Lilly’s self-pay price.
· Business
- Jim Cramer’s Charitable Trust Plans to Trim Cardinal Health and Eli Lilly
The planned sales would leave the portfolio with 375 Cardinal Health shares and 70 Eli Lilly shares.
· Insights & Views
- Peptide boom exposes evidence gaps as drug development and prescribing markets draw interest
Tirzepatide sales reached nearly $44 billion in the first nine months of 2026. Andreessen Horowitz examines evidence gaps in unapproved peptides and prospects for regulated drugs and prescribing businesses.
· Insights & Views
- Health Care ETF XLV Gains 9.53% in October Amid Tech Rotation
Regeneron and Eli Lilly rose, while Illumina and Solventum declined.
· Investing
- Healthcare Companies Beat Q3 EPS Estimates at a 96% Rate
Of 23 companies in the tally, 16 posted year-over-year earnings growth and 21 beat revenue estimates.
· Business
- AstraZeneca Shares Rise More Than 6% After Third-Quarter Profit Beat
Eli Lilly, Gilead Sciences, Amgen and Johnson & Johnson also advanced, and all five stocks reached all-time intraday highs.
· Investing
- Eli Lilly Posts $1.58 Billion in Third-Quarter Jardiance Sales, Up 64.5%
Jardiance sales increased 64.5% from the year-earlier quarter.
· Business
- Eli Lilly Raises 2026 Revenue Outlook to $91 Billion to $92 Billion
Third-quarter revenue rose 39% to $24.397 billion, led by Mounjaro and Zepbound sales.
· Business
- Merck, Eli Lilly Enter Earnings Reports With Declines Expected
Analysts project Merck’s earnings per share at $2.09, down 19% from a year earlier.
· Business
- Lilly Says Retatrutide Reduced A1C and Produced Weight Loss in Phase 3 Trial
The company said the treatment reduced A1C, a biomarker associated with diabetes, alongside weight loss.
· Business
- Eli Lilly Declares $1.73 Fourth-Quarter 2026 Dividend Payable Dec. 10
Shareholders must be on record Nov. 13 to receive the payment.
· Business
- Jim Cramer Says Cybersecurity Contact Sees Eli Lilly at $2 Trillion
Lilly’s market value was about $1.2 trillion, and its shares were up 10.5% month to date. The company reports third-quarter results Thursday.
· Investing
- Eli Lilly’s Olomorasib Posts a 62% Response Rate in Lung Cancer Study
The 77-patient combination group had median progression-free survival of 11.6 months. First randomized Phase 3 data are expected in the first half of 2027.
· Business
- Eli Lilly Posts 79.3% Response Rate for Ovarian Cancer Drug
Twenty-three of 29 women with measurable disease responded; the full cohort included 33. Lilly shares fell 2.54% on Oct. 23, before the release early Oct. 24.
· Business
- OKX Scheduled Eli Lilly-Linked LLYUSD Perpetual for Oct. 21
The USD-margined contract was scheduled to open at 4:30 a.m. ET, with trading access through OKX’s website, mobile app and API.
· Investing
- Eli Lilly Shares Set New Intraday Record at $1,311.21 on Oct. 20
The new high topped the prior intraday peak of $1,292.65 set Aug. 19; shares were up about 21% year to date.
· Investing
- EU Expert Panel Recommends Lilly’s Foundayo Weight-Loss Pill
The oral medicine contains orforglipron and has moved closer to possible approval in the European Union.
· Business
- Micron’s Market Value Slips Behind Lilly and Berkshire Hathaway
Micron’s market capitalization fell to about $985.5 billion after an 8.8% decline over five trading sessions.
· Investing
- Lilly’s Omvoh Shows 27.7% Disease Control Among Ulcerative Colitis Responders
In a separate Crohn’s disease analysis, 20.4% of patients on Omvoh achieved corticosteroid-free deep remission, compared with 2% on placebo.
· Business
- Lilly Trial Links Taltz-Zepbound Combination to Biomarker Changes
The Phase 3b study found higher rates of complete skin clearance and weight loss with the combination than with Taltz alone in adults with plaque psoriasis and obesity or overweight.
· Business
- NVIDIA, Eli Lilly Plan Up to $1 Billion for AI Drug Lab
The five-year partnership will link Lilly’s wet labs with computational systems and use NVIDIA’s BioNeMo platform and planned Vera Rubin architecture.
· Business